VP, Commercial Operations

Our mission is to liberate autoimmune patients through the curative potential of cell therapy. A new era of CAR T-cell therapy, Kyverna is pioneering a durable disease-clearing approach aiming for deep B cell depletion, an immune system reset, and long-term remission in autoimmune diseases. We believe the success of CAR T-cell therapies in B cell-driven hematological malignancies can be leveraged to deliver therapeutic benefits in patients living with autoimmune diseases.

We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world. Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology. This includes Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, as well as two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats, specifically designed for use in B cell-driven autoimmune diseases.